{
  "id": 600825,
  "title": "Why is Abcellera Biologics stock sliding today?",
  "url": "https://urgent.news/2026/08/11/why-is-abcellera-biologics-stock-sliding-today",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-11T21:05:30.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/why-is-abcellera-biologics-stock-sliding-today-93CH-4852766"
  },
  "original_language": "en",
  "account": "AbCellera Biologics' shares experienced a 4.1% decline in after-hours trading following the company's announcement of a $200 million underwritten public offering, primarily funded by the company itself. The capital raise aims to support research, development, and clinical advancement of its lead program, ABCL635, as well as general corporate purposes.\n\nThe positive news surrounding ABCL635, a potential first-in-class, non-hormonal antibody targeting the NK3R receptor for menopausal vasomotor symptoms, led to a 35% increase in the stock price during the previous session. In fact, Truist Securities raised its price target to $30 from $12, citing the potential peak risk-adjusted sales of $1.1 billion for ABCL635.\n\nHowever, the dilutive effect of the equity raise appears to be the primary driver behind the stock's decline. Investors are grappling with the trade-off between funding the company's future growth and the immediate impact of dilution. Meanwhile, the broader market showed no significant momentum to offset the decline, as the S&P 500 remained flat, the Dow Jones remained unchanged, and the NASDAQ was marginally positive.",
  "summary": null,
  "key_points": [
    "AbCellera Biologics shares declined 4.1% in after-hours trading",
    "Company announced $200 million underwritten public offering",
    "Dilutive effect of equity raise impacts stock price"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}